Showing results (251-260 of 353) with videos related to

Sort By:
Pageof 36
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.
Journal of Geriatric Oncology|October 23, 2021
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty toolElizabeth A Brem, Hongli Li, Anne W Beaven, et al.
JAMA Cardiology|March 29, 2023
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell LymphomaJenica N Upshaw, Jason Nelson, Angie Mae Rodday, et al.
Journal of General Internal Medicine|January 7, 2022
Development of High-Risk Geriatric Polypharmacy Electronic Clinical Quality Measures and a Pilot Test of EHR Nudges Based on These MeasuresStephen D Persell, Tiffany Brown, Jason N Doctor, et al.
British Journal of Haematology|April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
Clinical Lymphoma & Myeloma|September 1, 2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimensJennifer L Kelly, Stephen R Toothaker, Lauren Ciminello, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab EraBradley D Hunter, Megan Herr, Philip J Meacham, et al.
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes ProjectSam M Mbulaiteye, Lindsay M Morton, Joshua N Sampson, et al.
Oncotarget|July 6, 2015
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycyclineMary Pulvino, Luojing Chen, David Oleksyn, et al.
Pageof 36